Skip to content

With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area

With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area 1

The psoriasis marketplace has grown significantly in the last couple of years with newer agents being approved. With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area. Biologics and small-molecule drugs being developed to treat psoriasis are showing encouraging results, but high costs could limit their use. New biologic therapies that target the immunological faults underlying the disease have come through clinical trials with encouraging results. Essential to the project is the Manchester-based British Association of Dermatologists’ Biologic Interventions Register, a long-term safety register of patients on biologic therapies for psoriasis, which was set up in 2007 and now involves more than 10,000 patients and 150 dermatology centres across the UK and Ireland. Enter email address Submit. The psoriasis marketplace has grown significantly in the last couple of years with newer agents being approved. With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area. Photograph of Larisa.

With a new set of biologics entering the market, psoriasis is quickly becoming a dynamic therapeutic area 2The company’s latest report states that this impressive growth will be driven by the launch of novel psoriasis products, uptake of biosimilars for currently marketed biologics, and the expansion of existing psoriasis therapies such as dimethyl fumarate from Germany into the US and major European markets. Which innovative new product has been a game-changer this year? With many options currently available and additional therapies arriving in the market over the next few years, along with a constant need for reduced drug costs, GlobalData believes that further new entrants will find it difficult to distinguish themselves enough to enter the psoriasis therapy space. This collaboration positions BI 655066 as AbbVie’s lead investigational compound in psoriasis, complementing our robust immunology pipeline, said Michael E. Our expertise in developing and commercializing the world’s leading biologic, combined with Boehringer Ingelheim’s clinical success to-date will enable us to offer patients a new treatment option with the potential to meaningfully improve the standard of care. Our company remains strongly committed to establishing immunology as a core area of expertise and building our pipeline and capabilities in this important therapeutic area. 2 development for Crohn’s disease and asthma and is about to enter Phase 2 development for psoriatic arthritis. With many of these therapies being targeted for patient self-injection, devices must be as safe, simple, and convenient to use by the target population as possible. The LyoTwist monodose device family for dual-chamber cartridges is based on Ypsomed’s twisting method for reconstitution and priming and sets a new standard for preparation and injection of a freeze-dried drug in a disposable device.

Elsewhere however the approval of biologics for the treatment of psoriasis has seen growth in this area, albeit of a hetrogenous and regionally varied nature. Nabi Biopharmaceuticals’ NicVAX is in line to become the first nicotine vaccine to enter the market. Lower Back pain: New therapeutic opportunities open up for a new indication. Reporting the results at the American Association of Dermatology (AAD) conference in San Francisco, lead investigator Alexander Papp of Probity Medical Research in Canada described the results as compelling, given the high level of PASI 90 response and also that the benefits of therapy with BI 655066 seemed to extend beyond 12 weeks. Boehringer’s drug is the latest in a series of new biologic agents to show superior efficacy to Stelara, which has grown quickly to achieve sales of 1. AstraZeneca (AZ) and Amgen’s brodalumab and Eli Lilly’s ixekizumab are now competing for second place in the IL-17 inhibitor category – with equally impressive results in clinical trials – and could be on the market next year. Emerging markets are, of course, another area of key focus, providing a large new patient pool. As a result, there is huge potential for companies wishing to enter the autoimmune space in these regions. However, market potential is not directly proportional to patient potential, and recognising issues with patient access, insurance coverage, cost and affordability are vital for companies seeking to understand the real value of the opportunity in these countries.

Psoriasis Market Expected To Double By 2024

Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry s leading. Fueled by a very exciting portfolio of new products, oncology is set to become AstraZeneca’s sixth growth platform and play a large part in supporting our efforts to bring life-changing medicines to patients as well as delivering long-term growth. AZD9291 has been granted Breakthrough Therapy designation, Orphan Drug, and Fast Track status by the U.S. regulatory agency. Bristol-Myers Squibb has become a leader in an innovative area of cancer research and treatment known as immuno-oncology, which involves agents whose primary mechanism is to work directly with the body’s immune system to fight cancer. Targeted biotech drugs that attack specific biological molecules that cause disease are bringing new benefits even as they foment pricing dynamics that are very different from those of traditional drugs. Virtually all of these large-molecule, targeted biologics were created through the tools of modern biotechnology, usually involving recombinant DNA, molecular cloning, cell culture technology, or some combination. A second route to competition through targeting is through postapproval research on how a drug’s activity against a specific target may extend to other therapeutic areas, generating new uses for the drug. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of Nov. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. The worldwide market for biologics-therapeutic proteins and other biologically engineered drug products-now tops 100 billion a year. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Areas of Interest Bloomberg Law. 25 Additionally, the follow-on biologic applicant must provide a response for each patent the sponsor identified as being willing to license. The FDA Plan for Statutory Compliance addresses requirements set forth in Section 406 of the Food and Drug Administration Modernization Act of 1997 (FDAMA) (see Appendix A). The Agency’s current level of resources, however, cannot adequately address both goals in all of the product areas for which the Agency has responsibility. New technologies have provided an explosion of innovative diagnostic and therapeutic health products. Surveillance and compliance efforts also will continue to be directed toward identifying and taking action to correct the most serious health and safety problems associated with products that are in the marketplace or about to enter the market.

Advances In Drug Discovery: April 2009